The Pharma Data

JANUARY 24, 2021

. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $20.0

Marketing 40

Marketing Production Sales Containment 40

The Pharma Data

AUGUST 31, 2021

In addition, as part of the label update, this indication has been revised to be for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for any platinum-containing chemotherapy.

FDA Approval 52

FDA Approval Containment Clinical Development Trials 52

Drug Discovery World

SEPTEMBER 14, 2023

Europe has one of the highest rates of bladder cancer in the world 1 , with more than 203,000 patients diagnosed in 2020 alone 2. UC is the most common form 3 , and up to 20% of patients with metastatic UC (mUC) have FGFR alterations 4. 5 Only 8% of people diagnosed at a late, metastatic stage will survive for five years or more.

Containment 52

Containment Genetics FDA Approval Marketing 52

The Pharma Data

DECEMBER 30, 2020

Ensysce will use the funds to progress the clinical development of PF614, a first in class Trypsin Activated Abuse Protection (TAAP TM ) extended-release opioid prodrug, and its Multi-Pill Abuse Resistance (MPAR TM ) overdose protected counterpart, PF614-MPAR TM. “Our Global Emerging Markets (“GEM”) is a $3.4

Marketing 52

Marketing Production Drugs Containment 52

The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. For additional information, please visit www.lexpharma.com. Safe Harbor Statement.

Containment 52

Containment Clinical Development Development Protein 52

The Pharma Data

JANUARY 10, 2021

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

OCTOBER 26, 2020

(Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on Thursday, November 5, 2020.

Clinical Trials 52

Clinical Trials Clinical Trials Containment Clinical Development 52

pharmaphorum

AUGUST 31, 2022

It is actually the control formulation used in clinical development of its original product MED2005, which contained glyceryl trinitrate as an active ingredient. However, “the USA remains the largest market opportunity globally for ED treatments,” said Futura’s chief executive, James Barder.

Drugs 52

Drugs FDA Approval Production Marketing 52

The Pharma Data

NOVEMBER 12, 2020

Five Prime plans to use the net proceeds of the offering, together with other available funds, to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working capital and general corporate purposes.

Containment 40

Containment Sales Clinical Development Development 40

Delveinsight

AUGUST 24, 2020

The launch of the Pipeline therapies, increasing EPI prevalence shall fuel the Exocrine pancreatic insufficiency market size estimated to be approximately USD 1,695.26 However, the main pharmacologic treatment and the mainstay in the Exocrine pancreatic insufficiency market is Pancreatic enzyme replacement therapy (PERT).

Marketing 52

Marketing Production Pharma Companies Containment 52

The Pharma Data

JANUARY 13, 2021

Harpoon has four drug product candidates in clinical development for the treatment of solid and hematologic malignancies based on its proprietary TriTAC platform. In April 2020, Harpoon announced dosing of the first patient with HPN217 (BCMA TriTAC) in a Phase 1/2 clinical trial focused on relapsed/refractory multiple myeloma (RRMM).

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

Pfizer

AUGUST 3, 2022

We innovate every day leveraging our global footprint to accelerate the development and delivery of groundbreaking medicines and the hope of cures. Learn more about our Rare Disease portfolio and how we empower patients, engage communities in our clinical development programs, and support programs that heighten disease awareness.

Development 101

Development Vaccination Vaccine Production 101

Drug Discovery World

MARCH 29, 2023

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. According to EFPIA, RDP protects an innovator’s investment by granting a limited period of exclusivity on the data it generated, starting from marketing authorisation 4.

Clinical Trials 52

Clinical Trials Clinical Trials Production Medicine 52

The Pharma Data

JANUARY 24, 2021

Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. The global esophageal cancer drugs market is estimated to grow by USD $1.5

Drugs 52

Drugs Containment Development Sales 52

XTalks

APRIL 24, 2023

This is an increase from the EMA’s approval of two novel ATMPs with orphan designation in 2021 (although the marketing authorization for one of these ATMPs was withdrawn in the European Union in November 2021) and three novel ATMPs with orphan designation in 2020. How Can Study Protocols Be More Effective?

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

DECEMBER 14, 2020

The IND covers the development of Rabeximod in Covid-19 and other indications, such as rheumatoid arthritis, and is a prerequisite for a future validation of the company’s five recent patent applications in the US market. “Filing an IND with the FDA is an important step in the clinical development of Rabeximod.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Development Drugs 52

XTalks

AUGUST 15, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday that the US Food and Drug Administration (FDA) has granted marketing authorization for its combination treatment Akeega for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.

FDA Approval 52

FDA Approval Gene Hormones Licensing 52

pharmaphorum

APRIL 6, 2022

The ‘ gamification ’ of website design, app development, investment platforms, or just about any activity that exists on the internet, will contain examples of how this strategy maintains user engagement. Clinical development is no game.

Development 111

Development Clinical Development Production Trials 111

pharmaphorum

OCTOBER 2, 2020

COMP360 is a crystalline formulation of psilocybin in phase 2b clinical development in patients who have not responded to standard therapy for depression. Compass has a patented synthetic version of psilocybin, the active ingredient in magic mushrooms, and raised around $127.5 million with its IPO shortly after the announcement.

Medicine 122

Medicine Life Science FDA Approval Development 122

The Pharma Data

JANUARY 27, 2021

. A total of 15 patients have been recruited to date in the Phase I dose escalation part of the study, all of whom were late stage and have failed conventional treatments, including several lines of rituximab-containing therapies. ET ) to discuss the results and next steps in clinical development of BI-1206.

Antibody 52

Antibody Containment Development Trials 52

The Pharma Data

OCTOBER 18, 2020

Developed and marketed by Janssen, Tremfya (R) is the first approved fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. Tremfya (R) is a registered trademark of Janssen Biotech, Inc.

Clinical Development 40

Clinical Development Antibody Development Production 40

The Pharma Data

JANUARY 7, 2021

Cerecor intends to use the net proceeds of the offering for general corporate purposes and working capital, primarily to support the ongoing clinical development of key assets within its pipeline and for general and administrative expenses. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007.

Sales 52

Sales Clinical Development Development Containment 52

Pfizer

FEBRUARY 16, 2023

Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025, pending successful completion of the Phase 3 studies and subject to the agreement of these regulatory agencies to proposed modifications of the clinical trial plan.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

JANUARY 4, 2021

An experienced financial analyst and biotech executive, Dr. Farmer joins PureTech from BMO Capital Markets where he completed a 15-year career as a senior biotechnology equity analyst providing in-depth sector research for institutional investor clients. PureTech announced the appointment of George Farmer, Ph.D., as Chief Financial Officer.

Development 52

Development Marketing Production Medicine 52

XTalks

NOVEMBER 9, 2023

XTALKS WEBINAR: The Evolution of the Cardiovascular Clinical Development Landscape and Potential Role of GLP-1 RAs Live and On-Demand: Wednesday, December 6, 2023, at 11am EST (4pm GMT/UK) Register for this free webinar to learn about successful study outcomes in developing GLP1s to new therapeutic areas within cardiovascular medicine and more.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

The Pharma Data

DECEMBER 14, 2020

Attention: Equity Capital Markets, 55 East 52nd Street, 37th Floor, New York, NY 10055, by telephone at (888) 474-0200, or email: ecm.prospectus@evercore.com ; and Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, by email: prospectus@cantor.com.

Clinical Trials 40

Clinical Trials Clinical Trials Clinical Development Antibody 40

The Pharma Data

NOVEMBER 3, 2020

According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. Commenting on the announcement, Daniel Gruskin, M.D., LogicBio is headquartered in Lexington, Mass.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

Pfizer

SEPTEMBER 16, 2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union. Standard marketing authorization recommendation applies to all indications and formulations in the European Union, including COMIRNATY® Original/Omicron BA.4-5

Marketing 75

Marketing Vaccination Vaccine Clinical Trials 75

The Pharma Data

JANUARY 26, 2021

Securities and Exchange Commission (“ SEC “) in relation to up to US$250,000,000 in market value of its securities. capital markets. The Registration Statement also contains a preliminary prospectus supplement relating to an “at-the-market” sales agreement, which the Company expects to enter into with B. (the

Life Science 40

Life Science Sales Antibody Marketing 40

The Pharma Data

JANUARY 13, 2021

Complete approval for these indications is contingent upon results from ongoing randomized, controlled confirmatory clinical trials. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. Forward-Looking Statements.

Production 52

Production Trials Antibody Clinical Trials 52

The Pharma Data

JANUARY 10, 2021

Each of the first three dose cohorts contain up to six patients on ASLAN004 and two patients on placebo, and the expansion cohort will contain at least 12 patients on ASLAN004 and at least six patients on placebo. This release contains forward-looking statements. For additional information please visit www.aslanpharma.com.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Containment 52

The Pharma Data

DECEMBER 9, 2020

The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. All forward-looking statements contained in this press release speak only as of the date on which they were made.

Containment 52

Containment Trials Medicine Drugs 52

The Pharma Data

JANUARY 25, 2021

“The technology has a unique pharmacological profile, which is very different from other products in preclinical and clinical development in that it focuses on restoring function. All clinical development plans are subject to additional funding. Cautionary Note Regarding Forward-Looking Statements.

Clinical Development 40

Clinical Development Containment Development Research 40

The Pharma Data

DECEMBER 23, 2020

The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum. With this funding now complete, the Company is excited about its prospects for 2021 – as it pertains to its pharmaceutical development efforts. . NEW YORK, NY, Dec.

Life Science 52

Life Science Manufacturing Production Development 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Previously, he held roles as CMO at Trimeris Inc.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

JANUARY 20, 2021

Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50

DNA 40

DNA Containment Immune Response Sales 40

The Pharma Data

APRIL 27, 2021

the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorisation by the European Medicines Agency to prevent coronavirus disease 2019 (COVID-19) in people from 16 years of age. The information contained in this release is as of April 19, 2021. AUTHORIZED USE IN THE EU: COMIRNATY® ? Pfizer Disclosure Notice.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Trials 52